6, 2015 /PRNewswire/ -- Molecular Devices
, at SLAS 2015, launched a homogeneous, no-wash assay to measure ligand- and voltage-gated potassium channel activity.
These software enhancements maintain the IonWorks Barracuda System as best in class for automated electrophysiology systems on the market," said Mark Verheyden, president of Molecular Devices
Until now, the only way to obtain multifaceted measurements of an image set has been to employ techniques that require extensive training and that are complicated for even the most technically inclined researcher," said Mark Verheyden, President of Molecular Devices
Whether you are searching for rare events or investigating multifaceted cell signaling pathways, we are excited to offer twice the data points per image to decrease your time to perform cellular- and high-resolution screens" said Jennifer McKie, Senior Marketing Director, BioImaging at Molecular Devices
Corporation (NASDAQ:MDCC), Sunnyvale, Calif.
Drug developer MDS Inc (Concord, Ontario) said it is buying bioanalytical measurement systems maker Molecular Devices
Corp (Sunnyvale CA) for $615 million in cash.
New types of molecular devices
and catalysts could also emerge from these biologically based nanotubes, according to Juan R.
and ChanTest Corporation, leading providers of ion channel and GPCR drug discovery tools and solutions, have signed an agreement for Molecular Devices
to distribute ChanTest's extensive portfolio of ion channel and GPCR cell lines on a non-exclusive basis.
14, 2014 /PRNewswire/ -- Molecular Devices
, a leader in bioanalytical systems for drug discovery, life science research, and bioassay development, today announced the launch of the Digidata 1550A Low-Noise Data Acquisition System plus HumSilencer(TM) noise cancelling technology for the analog-to-digital conversion of biological signals measured in electrophysiology experiments.
Today, Molecular Devices
, LLC, announced the release of IonWorks Barracuda Software v2.
Sunnyvale, CA 3/9/05 -- Molecular Devices
has acquired Xsira Pharmaceuticals' Transfluor technology assets for $11 million in cash.
Since molecular devices
are more compact and less linear than conventional integrated circuits, they could facilitate better parallel processors.